JP2009508822A - 慢性腎症の処置のためのｈ因子およびその製造 - Google Patents

慢性腎症の処置のためのｈ因子およびその製造 Download PDF

Info

Publication number
JP2009508822A
JP2009508822A JP2008530342A JP2008530342A JP2009508822A JP 2009508822 A JP2009508822 A JP 2009508822A JP 2008530342 A JP2008530342 A JP 2008530342A JP 2008530342 A JP2008530342 A JP 2008530342A JP 2009508822 A JP2009508822 A JP 2009508822A
Authority
JP
Japan
Prior art keywords
factor
functional
treatment
plasma
functional factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008530342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009508822A5 (https=
Inventor
ペーター・グロンスキ
クリストフ・リヒト
ベルント・ホッペ
ペーター・ツィプフェル
クリスティーネ・スケルカ
Original Assignee
ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
インスティトゥート・フュル・ナトゥーアシュトフ−フォルシュング・エー・ファウ．−ハー・ケイ・イー
ウニヴェルジテート・ツー・ケルン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー, インスティトゥート・フュル・ナトゥーアシュトフ−フォルシュング・エー・ファウ．−ハー・ケイ・イー, ウニヴェルジテート・ツー・ケルン filed Critical ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー
Publication of JP2009508822A publication Critical patent/JP2009508822A/ja
Publication of JP2009508822A5 publication Critical patent/JP2009508822A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2008530342A 2005-09-19 2006-06-13 慢性腎症の処置のためのｈ因子およびその製造 Pending JP2009508822A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05020409 2005-09-19
PCT/EP2006/005631 WO2007038995A1 (en) 2005-09-19 2006-06-13 Factor h for the treatment of chronic nephropathies and production thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012116143A Division JP2012184251A (ja) 2005-09-19 2012-05-22 尿細管間質性線維症または進行性腎不全を処置するための機能性ｈ因子の使用

Publications (2)

Publication Number Publication Date
JP2009508822A true JP2009508822A (ja) 2009-03-05
JP2009508822A5 JP2009508822A5 (https=) 2009-06-25

Family

ID=36001069

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008530342A Pending JP2009508822A (ja) 2005-09-19 2006-06-13 慢性腎症の処置のためのｈ因子およびその製造
JP2012116143A Pending JP2012184251A (ja) 2005-09-19 2012-05-22 尿細管間質性線維症または進行性腎不全を処置するための機能性ｈ因子の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012116143A Pending JP2012184251A (ja) 2005-09-19 2012-05-22 尿細管間質性線維症または進行性腎不全を処置するための機能性ｈ因子の使用

Country Status (7)

Country Link
US (2) US20090118163A1 (https=)
EP (1) EP1928483B1 (https=)
JP (2) JP2009508822A (https=)
KR (1) KR20080048034A (https=)
AU (1) AU2006299293B2 (https=)
CA (1) CA2627264A1 (https=)
WO (1) WO2007038995A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014532401A (ja) * 2011-10-25 2014-12-08 ラボラトワール フランセ ドゥ フラクションマン エ デ バイオテクノロジーズＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ ヒトｈ因子の製造方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894145B1 (fr) * 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
ES2595059T3 (es) * 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano
LT2894165T (lt) 2008-11-10 2023-03-10 Alexion Pharmaceuticals, Inc. Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui
GB0904427D0 (en) 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
US8304524B2 (en) 2009-07-23 2012-11-06 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
FR2952640B1 (fr) 2009-11-16 2012-12-07 Lab Francais Du Fractionnement Procede de fabrication d'une preparation de facteur h
FR2952539B1 (fr) 2009-11-16 2012-01-13 Lab Francais Du Fractionnement Preparation d'un concentre de facteur h
GB0922659D0 (en) 2009-12-24 2010-02-10 Univ Edinburgh Factor H
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US9295713B2 (en) 2010-09-15 2016-03-29 Celldex Therapeutics, Inc. Treatment of chronic nephropathies using soluble complement receptor type I (sCR1)
RU2013121589A (ru) * 2010-10-13 2014-11-20 Октафарма Аг Способ очистки фактора комплемента н
FR2983212A1 (fr) 2011-11-28 2013-05-31 Lfb Biotechnologies Aptameres anti-fh, procede pour leur obtention et utilisations
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
AU2013203048A1 (en) 2013-03-15 2014-10-02 Baxalta GmbH Isolation of factor h from fraction i paste
AU2014306002B2 (en) 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62201822A (ja) * 1985-11-08 1987-09-05 Sankyo Co Ltd 自己免疫性疾病の予防・治療剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492325B1 (en) * 1998-05-22 2002-12-10 Boys Town National Research Hospital Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62201822A (ja) * 1985-11-08 1987-09-05 Sankyo Co Ltd 自己免疫性疾病の予防・治療剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5008012520; ＬＩＣＨＴ　Ｃ: ＡＭＥＲＩＣＡＮ　ＪＯＵＲＮＡＬ　ＯＦ　ＫＩＤＮＥＹ　ＤＩＳＥＡＳＥＳ Ｖ４５　Ｎ２, 200502, Ｐ４１５-４２１ *
JPN5008012521; ＨＯＧＡＳＥＮ　ＫＯＬＢＪＯＲＮ: ＭＯＬＥＣＵＬＡＲ　ＩＭＭＵＮＯＬＯＧＹ Ｖ３６　Ｎ４-５, 199903, Ｐ３０５，　ＡＢＳＴＲＡＣＴ　１０４ *
JPN5008012522; ＨＯＧＡＳＥＮ　ＫＯＬＢＪＯＲＮ: ＪＯＵＲＮＡＬ　ＯＦ　ＴＨＥ　ＡＭＥＲＩＣＡＮ　ＳＯＣＩＥＴＹ　ＯＦ　ＮＥＰＨＲＯＬＯＧＹ Ｖ９, 199709, Ｐ４７４Ａ-４７５Ａ，　ＡＢＳＴＲＡＣＴ　Ａ２２０６ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014532401A (ja) * 2011-10-25 2014-12-08 ラボラトワール フランセ ドゥ フラクションマン エ デ バイオテクノロジーズＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ ヒトｈ因子の製造方法

Also Published As

Publication number Publication date
EP1928483B1 (en) 2016-12-28
US20090118163A1 (en) 2009-05-07
JP2012184251A (ja) 2012-09-27
WO2007038995A1 (en) 2007-04-12
KR20080048034A (ko) 2008-05-30
US20110046062A1 (en) 2011-02-24
AU2006299293A1 (en) 2007-04-12
AU2006299293B2 (en) 2011-08-18
CA2627264A1 (en) 2007-04-12
EP1928483A1 (en) 2008-06-11
US10137165B2 (en) 2018-11-27

Similar Documents

Publication Publication Date Title
JP2012184251A (ja) 尿細管間質性線維症または進行性腎不全を処置するための機能性ｈ因子の使用
RU2396347C2 (ru) Модифицированные витамин к-зависимые полипептиды
US6846649B1 (en) Recombinant human mannan-binding lectin
JP5049271B2 (ja) 改変された活性化特性を有する第ｘ凝固因子ポリペプチド
US9347051B2 (en) Coagulation factor X polypeptides with modified activation properties
JP2020506693A (ja) アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体
EP3453400B1 (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
KR20250078598A (ko) 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법
CN106659771B (zh) 修饰的von Willebrand因子
JP6574431B2 (ja) Ｕｔｉ融合タンパク質
US20130337532A1 (en) Therapeutic polypeptides with increased in vivo recovery
KR102928495B1 (ko) 돌연변이된 폰 빌레브란트 인자
TWI589594B (zh) 用以治療和/或預防自體免疫疾病和發炎疾病的短合成胜肽
JP7604174B2 (ja) 血清アルブミンと成長ホルモンの融合蛋白質を含有する水性医薬組成物
JPWO2016104436A1 (ja) サイトカインストーム抑制剤
JP2024539242A (ja) 慢性腎疾患の治療のための改変カベオリン－１ペプチド
US20150366952A1 (en) Methods for reducing fibrosis induced by peritoneal dialysis
US20250177571A1 (en) Sequence of activated protein c
WO2008059917A1 (en) Thrombin mutant
JP2007532486A (ja) 組織因子経路インヒビターの投与による重度の市中肺炎の処置
HK40004111A (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
HK40004111B (en) Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120221

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120522

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20120629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120629

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121113